TFF3 interacts with LINGO2 to regulate EGFR activation for protection against colitis and gastrointestinal helminths. Read more about TFF3 interacts with LINGO2 to regulate EGFR activation for protection against colitis and gastrointestinal helminths.
Zebrafish behavioural profiling identifies GABA and serotonin receptor ligands related to sedation and paradoxical excitation. Read more about Zebrafish behavioural profiling identifies GABA and serotonin receptor ligands related to sedation and paradoxical excitation.
Author Correction: Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanisms. Read more about Author Correction: Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanisms.
A meta-analysis of genome-wide association studies identifies multiple longevity genes. Read more about A meta-analysis of genome-wide association studies identifies multiple longevity genes.
Hsp70 and Hsp40 inhibit an inter-domain interaction necessary for transcriptional activity in the androgen receptor. Read more about Hsp70 and Hsp40 inhibit an inter-domain interaction necessary for transcriptional activity in the androgen receptor.
Saturation mutagenesis of twenty disease-associated regulatory elements at single base-pair resolution. Read more about Saturation mutagenesis of twenty disease-associated regulatory elements at single base-pair resolution.
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. Read more about Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Read more about Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.
Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanisms. Read more about Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanisms.
Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer. Read more about Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer.
